IGEM:IMPERIAL/2009/123

=Creating ‘The E.ncapsulator’: in situ manufacture and oral delivery of human biopharmaceuticals=

Furthermore, in order to create E.ncapsulator tablets for oral delivery, there has been much focus on designing and engineering a number of modules for implementation in E.coli. The modularity that is central to our project will be evident in the areas of protein drug production, self-encapsulation and genomic neutralisation. Utilising the E.coli bacterium, we are creating a re-usable chassis that will allow the development of a range of biopharmaceuticals to be delivered to the gut. Our E.ncapsulator is therefore intended as an elegant solution to, not one, but a range of human ailments and conditions, which cannot currently be successfully treated by oral drugs.

The first module involves engineering E.coli to synthesise the protein drug of interest to a tuneable threshold. Once accomplished, activation of module two initiates the encapsulation phase, in which E.coli coats itself in a protective layer of colanic acid to form the E.ncapsulator. This protective capsule is what shields the biopharmaceutical against the harsh acidic environment of the stomach. The third module, genomic neutralisation, is composed of a ‘suicide trigger’ mechanism that destroys the genetic material of the bacteria. Finally, once in the small intestine, the capsule will be degraded, thereby releasing the designed biopharmaceutical to the gut micro biota where it can carry out its intended function.

The self-encapsulation of a synthetic biology chassis is new to iGEM and represents a completely novel and innovative approach to biopharmaceutical design, manufacture and delivery. Throughout the project we have followed an engineering approach that incorporates modular design, detailed modelling and simulation as well as systematic integration. Using such an approach, we are hopeful that the E.ncapsulator will be coming soon to a Pharmacy near you!